Loading…

ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resemble...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2023-03, Vol.14, p.1093332-1093332
Main Authors: Bae, Song Yi, Bergom, Hannah E, Day, Abderrahman, Greene, Joseph T, Sychev, Zoi E, Larson, Gabrianne, Corey, Eva, Plymate, Stephen R, Freedman, Tanya S, Hwang, Justin H, Drake, Justin M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463
cites cdi_FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463
container_end_page 1093332
container_issue
container_start_page 1093332
container_title Frontiers in endocrinology (Lausanne)
container_volume 14
creator Bae, Song Yi
Bergom, Hannah E
Day, Abderrahman
Greene, Joseph T
Sychev, Zoi E
Larson, Gabrianne
Corey, Eva
Plymate, Stephen R
Freedman, Tanya S
Hwang, Justin H
Drake, Justin M
description Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resembles other SCN carcinomas clinically, histologically and in gene expression. Here, we leveraged SCN phenotype scores of various cancer cell lines and gene depletion screens from the Cancer Dependency Map (DepMap) to identify vulnerabilities in NEPC. We discovered ZBTB7A, a transcription factor, as a candidate promoting the progression of NEPC. Cancer cells with high SCN phenotype scores showed a strong dependency on RET kinase activity with a high correlation between RET and ZBTB7A dependencies in these cells. Utilizing informatic modeling of whole transcriptome sequencing data from patient samples, we identified distinct gene networking patterns of ZBTB7A in NEPC versus prostate adenocarcinoma. Specifically, we observed a robust association of ZBTB7A with genes promoting cell cycle progression, including apoptosis regulating genes. Silencing ZBTB7A in a NEPC cell line confirmed the dependency on ZBTB7A for cell growth suppression of the G1/S transition in the cell cycle and induction of apoptosis. Collectively, our results highlight the oncogenic function of ZBTB7A in NEPC and emphasize the value of ZBTB7A as a promising therapeutic strategy for targeting NEPC tumors.
doi_str_mv 10.3389/fendo.2023.1093332
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3e48ddb167a545a593cf9fd00b156061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3e48ddb167a545a593cf9fd00b156061</doaj_id><sourcerecordid>2802424952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463</originalsourceid><addsrcrecordid>eNpVkUtPGzEQgK2qVUGUP8Ch2mMvCX7v-lQF1AISUi_0wsWatcfUaGOn9m4k_j0bEhD4MtY8vrH8EXLG6FKIzpwHTD4vOeViyagRQvBP5JhpLRdcGP753f2InNb6SOcjKTOm-0qOREu1apU-Jqv7i7uLdtVAbaBJeYtDs52GhAX6OMTxqYmpSTiVvFvnSkzYbEquI4zYOEgOyzfyJcBQ8fQQT8jf37_uLq8Xt3-ubi5XtwsntRkXputFi4BM9Soo1skgFAUwgJ5xBbKlFAP3HCR2zKGZszQYcN5jACG1OCE3e67P8Gg3Ja6hPNkM0b4kcnmwUMboBrQCZed9z3QLSipQRrhggqe0Z0pTzWbWzz1rM_Vr9A7TWGD4AP1YSfGffchbyyg1VCkxE34cCCX_n7COdh2rw2GAhHmqlneUSy6N4nMr37e6-eNqwfC2h1G7c2lfXNqdS3twOQ99f__Ct5FXc-IZDNCbxw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2802424952</pqid></control><display><type>article</type><title>ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer</title><source>PubMed Central</source><creator>Bae, Song Yi ; Bergom, Hannah E ; Day, Abderrahman ; Greene, Joseph T ; Sychev, Zoi E ; Larson, Gabrianne ; Corey, Eva ; Plymate, Stephen R ; Freedman, Tanya S ; Hwang, Justin H ; Drake, Justin M</creator><creatorcontrib>Bae, Song Yi ; Bergom, Hannah E ; Day, Abderrahman ; Greene, Joseph T ; Sychev, Zoi E ; Larson, Gabrianne ; Corey, Eva ; Plymate, Stephen R ; Freedman, Tanya S ; Hwang, Justin H ; Drake, Justin M</creatorcontrib><description>Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resembles other SCN carcinomas clinically, histologically and in gene expression. Here, we leveraged SCN phenotype scores of various cancer cell lines and gene depletion screens from the Cancer Dependency Map (DepMap) to identify vulnerabilities in NEPC. We discovered ZBTB7A, a transcription factor, as a candidate promoting the progression of NEPC. Cancer cells with high SCN phenotype scores showed a strong dependency on RET kinase activity with a high correlation between RET and ZBTB7A dependencies in these cells. Utilizing informatic modeling of whole transcriptome sequencing data from patient samples, we identified distinct gene networking patterns of ZBTB7A in NEPC versus prostate adenocarcinoma. Specifically, we observed a robust association of ZBTB7A with genes promoting cell cycle progression, including apoptosis regulating genes. Silencing ZBTB7A in a NEPC cell line confirmed the dependency on ZBTB7A for cell growth suppression of the G1/S transition in the cell cycle and induction of apoptosis. Collectively, our results highlight the oncogenic function of ZBTB7A in NEPC and emphasize the value of ZBTB7A as a promising therapeutic strategy for targeting NEPC tumors.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2023.1093332</identifier><identifier>PMID: 37065756</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>cancer dependency map (DepMap) ; castration-resistant prostate cancer (CRPC) ; Cell Line, Tumor ; DNA-Binding Proteins - genetics ; Endocrinology ; Humans ; Male ; neuroendocrine prostate cancer (NEPC) ; Neuroendocrine Tumors - genetics ; Neuroendocrine Tumors - pathology ; Prostatic Neoplasms - pathology ; RET receptor tyrosine kinase ; small-cell neuroendocrine (SCN) ; Transcription Factors - metabolism ; ZBTB7A</subject><ispartof>Frontiers in endocrinology (Lausanne), 2023-03, Vol.14, p.1093332-1093332</ispartof><rights>Copyright © 2023 Bae, Bergom, Day, Greene, Sychev, Larson, Corey, Plymate, Freedman, Hwang and Drake.</rights><rights>Copyright © 2023 Bae, Bergom, Day, Greene, Sychev, Larson, Corey, Plymate, Freedman, Hwang and Drake 2023 Bae, Bergom, Day, Greene, Sychev, Larson, Corey, Plymate, Freedman, Hwang and Drake</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463</citedby><cites>FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090553/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090553/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37065756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bae, Song Yi</creatorcontrib><creatorcontrib>Bergom, Hannah E</creatorcontrib><creatorcontrib>Day, Abderrahman</creatorcontrib><creatorcontrib>Greene, Joseph T</creatorcontrib><creatorcontrib>Sychev, Zoi E</creatorcontrib><creatorcontrib>Larson, Gabrianne</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Plymate, Stephen R</creatorcontrib><creatorcontrib>Freedman, Tanya S</creatorcontrib><creatorcontrib>Hwang, Justin H</creatorcontrib><creatorcontrib>Drake, Justin M</creatorcontrib><title>ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resembles other SCN carcinomas clinically, histologically and in gene expression. Here, we leveraged SCN phenotype scores of various cancer cell lines and gene depletion screens from the Cancer Dependency Map (DepMap) to identify vulnerabilities in NEPC. We discovered ZBTB7A, a transcription factor, as a candidate promoting the progression of NEPC. Cancer cells with high SCN phenotype scores showed a strong dependency on RET kinase activity with a high correlation between RET and ZBTB7A dependencies in these cells. Utilizing informatic modeling of whole transcriptome sequencing data from patient samples, we identified distinct gene networking patterns of ZBTB7A in NEPC versus prostate adenocarcinoma. Specifically, we observed a robust association of ZBTB7A with genes promoting cell cycle progression, including apoptosis regulating genes. Silencing ZBTB7A in a NEPC cell line confirmed the dependency on ZBTB7A for cell growth suppression of the G1/S transition in the cell cycle and induction of apoptosis. Collectively, our results highlight the oncogenic function of ZBTB7A in NEPC and emphasize the value of ZBTB7A as a promising therapeutic strategy for targeting NEPC tumors.</description><subject>cancer dependency map (DepMap)</subject><subject>castration-resistant prostate cancer (CRPC)</subject><subject>Cell Line, Tumor</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Male</subject><subject>neuroendocrine prostate cancer (NEPC)</subject><subject>Neuroendocrine Tumors - genetics</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>RET receptor tyrosine kinase</subject><subject>small-cell neuroendocrine (SCN)</subject><subject>Transcription Factors - metabolism</subject><subject>ZBTB7A</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtPGzEQgK2qVUGUP8Ch2mMvCX7v-lQF1AISUi_0wsWatcfUaGOn9m4k_j0bEhD4MtY8vrH8EXLG6FKIzpwHTD4vOeViyagRQvBP5JhpLRdcGP753f2InNb6SOcjKTOm-0qOREu1apU-Jqv7i7uLdtVAbaBJeYtDs52GhAX6OMTxqYmpSTiVvFvnSkzYbEquI4zYOEgOyzfyJcBQ8fQQT8jf37_uLq8Xt3-ubi5XtwsntRkXputFi4BM9Soo1skgFAUwgJ5xBbKlFAP3HCR2zKGZszQYcN5jACG1OCE3e67P8Gg3Ja6hPNkM0b4kcnmwUMboBrQCZed9z3QLSipQRrhggqe0Z0pTzWbWzz1rM_Vr9A7TWGD4AP1YSfGffchbyyg1VCkxE34cCCX_n7COdh2rw2GAhHmqlneUSy6N4nMr37e6-eNqwfC2h1G7c2lfXNqdS3twOQ99f__Ct5FXc-IZDNCbxw</recordid><startdate>20230329</startdate><enddate>20230329</enddate><creator>Bae, Song Yi</creator><creator>Bergom, Hannah E</creator><creator>Day, Abderrahman</creator><creator>Greene, Joseph T</creator><creator>Sychev, Zoi E</creator><creator>Larson, Gabrianne</creator><creator>Corey, Eva</creator><creator>Plymate, Stephen R</creator><creator>Freedman, Tanya S</creator><creator>Hwang, Justin H</creator><creator>Drake, Justin M</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230329</creationdate><title>ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer</title><author>Bae, Song Yi ; Bergom, Hannah E ; Day, Abderrahman ; Greene, Joseph T ; Sychev, Zoi E ; Larson, Gabrianne ; Corey, Eva ; Plymate, Stephen R ; Freedman, Tanya S ; Hwang, Justin H ; Drake, Justin M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>cancer dependency map (DepMap)</topic><topic>castration-resistant prostate cancer (CRPC)</topic><topic>Cell Line, Tumor</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Male</topic><topic>neuroendocrine prostate cancer (NEPC)</topic><topic>Neuroendocrine Tumors - genetics</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>RET receptor tyrosine kinase</topic><topic>small-cell neuroendocrine (SCN)</topic><topic>Transcription Factors - metabolism</topic><topic>ZBTB7A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bae, Song Yi</creatorcontrib><creatorcontrib>Bergom, Hannah E</creatorcontrib><creatorcontrib>Day, Abderrahman</creatorcontrib><creatorcontrib>Greene, Joseph T</creatorcontrib><creatorcontrib>Sychev, Zoi E</creatorcontrib><creatorcontrib>Larson, Gabrianne</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Plymate, Stephen R</creatorcontrib><creatorcontrib>Freedman, Tanya S</creatorcontrib><creatorcontrib>Hwang, Justin H</creatorcontrib><creatorcontrib>Drake, Justin M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bae, Song Yi</au><au>Bergom, Hannah E</au><au>Day, Abderrahman</au><au>Greene, Joseph T</au><au>Sychev, Zoi E</au><au>Larson, Gabrianne</au><au>Corey, Eva</au><au>Plymate, Stephen R</au><au>Freedman, Tanya S</au><au>Hwang, Justin H</au><au>Drake, Justin M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2023-03-29</date><risdate>2023</risdate><volume>14</volume><spage>1093332</spage><epage>1093332</epage><pages>1093332-1093332</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resembles other SCN carcinomas clinically, histologically and in gene expression. Here, we leveraged SCN phenotype scores of various cancer cell lines and gene depletion screens from the Cancer Dependency Map (DepMap) to identify vulnerabilities in NEPC. We discovered ZBTB7A, a transcription factor, as a candidate promoting the progression of NEPC. Cancer cells with high SCN phenotype scores showed a strong dependency on RET kinase activity with a high correlation between RET and ZBTB7A dependencies in these cells. Utilizing informatic modeling of whole transcriptome sequencing data from patient samples, we identified distinct gene networking patterns of ZBTB7A in NEPC versus prostate adenocarcinoma. Specifically, we observed a robust association of ZBTB7A with genes promoting cell cycle progression, including apoptosis regulating genes. Silencing ZBTB7A in a NEPC cell line confirmed the dependency on ZBTB7A for cell growth suppression of the G1/S transition in the cell cycle and induction of apoptosis. Collectively, our results highlight the oncogenic function of ZBTB7A in NEPC and emphasize the value of ZBTB7A as a promising therapeutic strategy for targeting NEPC tumors.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37065756</pmid><doi>10.3389/fendo.2023.1093332</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2023-03, Vol.14, p.1093332-1093332
issn 1664-2392
1664-2392
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3e48ddb167a545a593cf9fd00b156061
source PubMed Central
subjects cancer dependency map (DepMap)
castration-resistant prostate cancer (CRPC)
Cell Line, Tumor
DNA-Binding Proteins - genetics
Endocrinology
Humans
Male
neuroendocrine prostate cancer (NEPC)
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - pathology
Prostatic Neoplasms - pathology
RET receptor tyrosine kinase
small-cell neuroendocrine (SCN)
Transcription Factors - metabolism
ZBTB7A
title ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A15%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ZBTB7A%20as%20a%20novel%20vulnerability%20in%20neuroendocrine%20prostate%20cancer&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Bae,%20Song%20Yi&rft.date=2023-03-29&rft.volume=14&rft.spage=1093332&rft.epage=1093332&rft.pages=1093332-1093332&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2023.1093332&rft_dat=%3Cproquest_doaj_%3E2802424952%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-98b37eae15b5f5184f350aa9aed125a4700ef2d2a4e81ce9d120f9acddefa3463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2802424952&rft_id=info:pmid/37065756&rfr_iscdi=true